Selected Publications

Non-Pharmaceutical Research

  • Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis R, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Monés JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. 2017 Oct.
  • Holz FG, Sadda SR, Staurenghi G, Lindner M, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Curcio CA, Danis R, Fleckenstein M, Freund KB, Grunwald J, Guymer R, Hoyng CB, Jaffe GJ, Liakopoulos S, Monés JM, Oishi A, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Schmitz-Valckenberg S; CAM group. Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. Ophthalmology. 2017 Jan 18.
  • Schmitz-Valckenberg S, Brinkmann CK, Fleckenstein M, Heimes B, Liakopoulos S, Spital G, Holz FG. [Pitfalls in retinal optical coherence tomography imaging]. Ophthalmologe. 2017 Feb 14.
  • Schick T, Ersoy L, Hoyng CB, Kirchhof B, Liakopoulos S. Phenotype Characteristics of Fellow Eyes in Patients With Early Onset of Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7269-73.
  • Ersoy L, Ristau T, Kirchhof B, Liakopoulos S. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):889-97.
  • Ristau T, Keane PA, Walsh AC, Engin A, Mokwa N, Kirchhof B, Sadda SR, Liakopoulos S. Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration. Ophthalmologica. 2014;231(1):37-44.
  • Liakopoulos S, Keane PA, Ristau T, Kirchhof B, Walsh AC, Sadda SR. Atypical outer retinal fluid accumulation in choroidal neovascularization: a novel OCT finding. Ophthalmic Surg Lasers Imaging Retina. 2013 Nov-Dec;44(6 Suppl):S11-8.
  • Mokwa NF, Ristau T, Keane PA, Kirchhof B, Sadda SR, Liakopoulos S. Grading of Age-Related Macular Degeneration: Comparison between Color Fundus Photography, Fluorescein Angiography, and Spectral Domain Optical Coherence Tomography. J Ophthalmol. 2013;2013:385915.
  • Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012 Sep;57(5):389-414.
  • Keane PA, Liakopoulos S, Jivrajka RV, Chang KT, Alasil T, Walsh AC, Sadda SR. Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3378-85.

NCT02194803 ORCA, Observational Study

  • Brinkmann CK, Chang P, Schick T, Heimes B, Vogeler J, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S. Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study). Ophthalmologe. 2018.
  • Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, Voegeler J, Koch M, Liakopoulos S, Schmitz-Valckenberg S, Spital G, Ocean Study Group. Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany. Diabetes Ther. 2018;9(6):2271-2289.
  • Ziemssen F, Bertelmann T, Hufenbach U, Scheffler M, Liakopoulos S, Schmitz-Valckenberg S. Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe. 2016;113(2):143-151.

Abstracts NCT02194803 ORCA, Observational Study 

  • Liakopoulos S, for the ORCA Study Group. IVOM-Therapie in Deutschland, neue Erkenntnisse zur Versorgungsqualität. Augenärztliche Akademie Deutschlands (AAD), 2019 (Presentation)
  • Liakopoulos S, for the ORCA Study Group. Update zu den aktuellen Versorgungsanalysen AMD und DMÖ. Makula Update, 2019 (Presentation)
  • Schmitz-Valckenberg S, Brinkmann CK, Chang P, Schick T, Heimes B, Voegeler J, Hägele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G. Differentialdiagnose der AMD: Lehren aus der ORCA-Studie. Deutsche Ophthalmochirurgie (DOC), 2018 (Presentation)
  • Schmitz-Valckenberg S, Brinkmann CK, Chang P, Schick T, Heimes B, Voegeler J, Hägele B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G. Probing Reality in Anti-VEGF-Therapy – Learnings from the ORCA Project. ISS, 2018 (Presentation)
  • Schmitz-Valckenberg S, Liakopoulos S, Ziemssen F, Müller B, Voegeler J, Brinkmann, C, Spital G. Interpretation of SD-OCT imaging data in real-life conditions versus standardized reading center analysis in eyes with diabetic macular edema (DME) – 24 months results of the ORCA study. The European Society of Retina Specialists (EURETINA), 2018 (Presentation)
  • Ziemssen F, Voegeler J, Spital G, Liakopoulos S, Schmitz-Valckenberg S, Bertelmann T. Reporting of safety events across anti-VEGF indications and the Pharmacovigilance approach: Findings from the non-interventional OCEAN study. The Association for Research in Vision and Ophthalmology (ARVO), 2018 (Poster)
  • Callizo J, Bertelmann T, Voegeler J, Schmitz-Valckenberg S, Spital G, Feltgen, N, Liakopoulos S, Ziemssen F. Real-life effectiveness of ranibizumab in RVO patients in a prospective, non-interventional trial over 12 months (OCEAN study). The Association for Research in Vision and Ophthalmology (ARVO), 2017 (Poster)
  • Callizo J, Schmitz-Valckenberg S, Spital G, Liakopoulos S, Bertelmann T, Voegeler J, Koch M, Feltgen N, Ziemssen F. Erläuterung des Behandlungserfolges bei RVV-Patienten mit VEGF-Inhibition in einer prospektiven, nicht-interventionellen Studie über 12 Monate. German Ophthalmological Society (DOG), 2017 (Presentation)
  • Feltgen N, Ziemssen F, Spital G, Liakopoulos S, Voegeler J, Koch M, Schmitz-Valckenberg S, OCEAN Study Group. Analysis of baseline factors affecting outcome of RVO patients to ranibizumab therapy in a prospective, non-interventional trial: the OCEAN study. The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Gunnemann F, Voegeler J, Schmitz-Valckenberg S, Spital G, Liakopoulos S, Ziemssen F. Influence of OCT-examination during ranibizumab treatment of AMD patients in a real-life setting (OCEAN study). The Association for Research in Vision and Ophthalmology (ARVO), 2017 (Poster)
  • Kuehlewein L, Koch M, Voegeler J. Bertelmann T, Schmitz-Valckenberg S, Liakopoulos S, Spital G, OCEAN Study Group. Insights into the real-life data collection of DME patients treated with ranibizumab over 24 months (OCEAN study). The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Liakopoulos S, Spital G, Voegeler J, Koch M, Ziemssen F, Kirchhof B, Holz F, Pauleikhoff D, Schmitz-Valckenberg S. Evaluation der SD-OCT- Befundung bei Patienten mit neovaskulärer AMD im Behandlungsalltag – Zwei-Jahres-Ergebnisse der ORCA Studie. German Ophthalmological Society (DOG), 2017 (Presentation)
  • Schmitz-Valckenberg S, Spital G, Ziemssen F, Voegeler J, Koch M, Brinkmann C, Liakopoulos S. Interpretation of SD-OCT imaging data in real-life conditions versus standardized reading center analysis in eyes with neovascular age-related macular degeneration – 24 months results of the ORCA Project. The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Thiele S, Ziemssen F, Spital G, Schmitz-Valckenberg S, Voegeler J, Koch M, Bertelsmann T, Liakopoulos S, OCEAN Study Group. Quality of life of patients with nAMD treated with ranibizumab under real life conditions: the OCEAN study. The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Wachtlin J, Schmitz-Valkenberg S, Spital G, Voegeler J, Koch M, Liakopoulos S, Bertelmann T, Ziemssen F, OCEAN Studiengruppe. Unterschiede beim Ansprechen von Patienten mit nAMD auf die anti-VEGF Behandlung. OCEAN: Observation in treatment patterns with Lucentis and real life ophthalmic monitoring, including optional OCT in Approved Indications. German Ophthalmological Society (DOG), 2017 (Presentation)
  • Wachtlin J, Schmitz-Valkenberg S, Spital G, Voegeler J, Koch M, Liakopoulos S, Bertelmann T, Ziemssen F. Anti-VEGF Therapie bei neovaskulärer AMD im Behandlungsalltag in Deutschland – 2 Jahres Follow-up der OCEAN Studie. German Ophthalmological Society (DOG), 2017 (Presentation)
  • Ziemssen F, Schmitz-Valckenberg S, Spital G, Voegeler J, Koch M, Bertelmann T, Liakopoulos S. Real world evidence of today’s challenges of ranibizumab treatment in nAMD patients (OCEAN study). The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Ziemssen F, Voegeler J, Schmitz-Valckenberg S, Spital G, Liakopoulos S. Dependency of BCVA and ranibizumab treatment frequency of DME patients in a real-life setting (OCEAN study). The Association for Research in Vision and Ophthalmology (ARVO), 2017 (Poster)
  • Brinkmann CK, Schick T, Bertelmann T, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S. Initial diagnosis before initiation of anti-VEGF therapy: comparison between treating ophthalmologists versus reading centers in the ORCA-study. German Ophthalmological Society (DOG), 2016 (Presentation)
  • Liakopoulos S. Update OCEAN and ORCA Study. Verein Rheinisch-Westfälischer Augenärzte (RWA), Bonn, 2016 (Presentation)
  • Spital G, Brinkmann CK, Schick T, Bertelmann T, Kirchhof B, Holz FG, Heimes B, Pauleikhoff D, Ziemssen F, Schmitz-Valckenberg S, Liakopoulos S. SD-OCT Befundung im Praxisalltag im Vergleich zur standardisierten Auswertung durch Reading Center – Baseline Daten der ORCA-Studie. Retinologische Gesellschaft (RG), 2016 (Presentation)
  • Liakopoulos S, Heimes B, Brinkmann CK, Schick T, Bertelmann T, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Schmitz-Valckenberg S, Spital G. SD-OCT Befundung im Praxisalltag im Vergleich zur standardisierten Auswertung durch Reading Center – Baseline Daten der ORCA-Studie. European School for Advanced Studies in Ophthalmology (ESASO), 2015 (Poster)
  • Liakopoulos S, Schmitz-Valckenberg S, Spital G, Bertelmann T, Holz FG, Ziemssen F, OCEAN Investigators. OCEAN: First data of patients with macular edema due to central retinal vein occlusion (CRVO) after completed patient recruitment – baseline characteristics and 1-year follow-up data. World Ophthalmology Congress (WOC), 2015 (Presentation)
  • Liakopoulos S, Schmitz-Valckenberg S, Spital G, Holz FG, Wiedon A, Ziemssen F, ORCA Investigators. SD-OCT-Befundung im Praxisalltag im Vergleich zur standardisierten Auswertung durch Reading Center. Zwischenergebnisse der ORCA-Studie. Verein Rheinisch-Westfälischer Augenärzte (RWA), 2015 (Presentation)
  • Liakopoulos S, Schmitz-Valckenberg S, Heimes T, Schick T, Brinkmann CK, Wiedon A, Knorr T, Ziemssen F, Holz FG, Spital G. SD-OCT diagnosis in real-life conditions compared to standardized analysis by 3 independent reading centers - ORCA study. German Ophthalmological Society (DOG), 2015 (Presentation)
  • Liakopoulos S, Schmitz-Valckenberg S, Spital G, Bertelmann T, Holz FG, Ziemssen F, OCEAN Investigators. OCEAN: First Data Of Patients With Macular Edema Due To Central Retinal Vein Occlusion After Completed Patient Recruitment. European School for Advanced Studies in Ophthalmology (ESASO), 2015 (Presentation)
  • Scheffler M, Schmitz-Vlackenberg S, Ziemssen F, Liakopoulos S, Spital G, Bertelmann T, Holz FG, OCEAN Investigators. OCEAN: First 2-Year Results Of Patients With Neovascular Age-Related Macular Degeneration After Completed Patient Recruitment. European School for Advanced Studies in Ophthalmology (ESASO), 2015 (Presentation)
  • Schmitz-Valckenberg S, Liakopoulos S, Spital G, Ziemssen F, Knorr T, Holz FG, ORCA Study Investigators. SD-OCT diagnosis in real-life conditions compared to standardized analysis by 3 independent reading centers – ORCA study. The European Society of Retina Specialists (EURETINA), 2015 (Presentation)
  • Spital G, Schmitz-Valckenberg S, Liakopoulos S, Bertelmann T, Holz FG, Ziemssen F, OCEAN Investigators. OCEAN: First data of patients with diabetic macular edema (DME) after completed patient recruitment – effectiveness of ranibizumab therapy after 1 year. World Ophthalmology Congress (WOC), 2015 (Presentation)
  • Spital G, Schmitz-Valckenberg S, Liakopoulos S, Bertelmann T, Holz FG, Ziemssen F, OCEAN Investigators. OCEAN: First Data of Patients With Diabetic Macular Edema After Completed Patient Recruitment–effectiveness Of Ranibizumab Therapy After 1 Year. European School for Advanced Studies in Ophthalmology (ESASO), 2015 (Presentation)
  • Ziemssen F, Schmitz-Valckenberg S, Liakopoulos S, Spital G, Knorr T, Holz FG. Do the baseline characteristics of study populations correspond to real-life cohorts? Experience of the prospective healthcare research project “OCEAN”. The European Society of Retina Specialists (EURETINA), 2015 (Presentation)
  • Ziemssen F, Schmitz-Valckenberg S, Liakopoulos S, Spital G, Knorr T, Holz FG. OCEAN Study – Baseline Demographics of full-analysis set after completion of enrollment. AMD Meeting Baden Baden, 2015 (Presentation)
  • Berk H, Esser P, Engels B, Wiedon A, Ziemssen F, OCEAN-Study Group. 12-month real-life data of patients with neovascular age related macular degeneration: prospective results of a single OCEAN center. European School for Advanced Studies in Ophthalmology (ESASO), 2014 (Presentation)
  • Heimes B, Ziemssen F, Schmitz-Valckenberg S, Liakopoulos S, Spital G, Wiedon A, Holz FG. OCEAN: Erste multizentrische Real-Life Daten der Indikation DMÖ. Deutsche Ophthalmochirurgie (DOC), 2014 (Presentation)
  • Liakopoulos S, Schmitz-Valckenberg S, Spital G, Wiedon A, Ziemssen F, Holz FG, Orca Investigators. SD-OCT-Befundung im Praxisalltag im Vergleich zur standardisierten Auswertung durch Reading Center. Erste Zwischenergebnisse der ORCA-Studie. German Ophthalmological Society (DOG), 2014 (Presentation)
  • o.V. ORCA - Informationen & Hilfestellungen. Makulaupdate, 2014 (Presentation)
  • o.V. Interimsanalyse - Feuchte AMD -. Augenärztliche Akademie Deutschland (AAD), 2014 (Presentation)
  • Schmitz-Valckenberg S, Liakopoulos S, Spital G, Ziemssen F, Wiedon A, Holz FG. ORCA - Comparison of SD-OCT image analysis in real life compared to standardized reading center analysis. The European Society of Retina Specialists (EURETINA), 2014 (Presentation)
  • Ziemssen F, Liakopoulos S, Schmitz-Valckenberg S, Spital G, Wiedon A, Holz FG. OCEAN Study – German non-interventional trial to observe anti-VEGF treatment patterns with Ranibizumab in all approved indications under real-life conditions. The European Society of Retina Specialists (EURETINA), 2014 (Presentation)
  • Ziemssen F, Liakopoulos S, Schmitz-Valckenberg S, Spital G, Wiedon A, Holz FG, OCEAN Investigators. OCEAN-Studie: Real-Life Daten zur visusbezogenen Lebensqualität von AMD-Patienten unter Ranibizumab-Therapie. German Ophthalmological Society (DOG), 2014 (Presentation)
  • Ziemssen F, Spital G, Schmitz-Valckenberg S, Liakopoulos S, Wiedon A, Holz FG, OCEAN Investigators. OCEAN-Studie: Interimsdaten aus dem Behandlungsalltag von Patienten mit retinalen Venenverschlüssen. German Ophthalmological Society (DOG), 2014 (Presentation)
  • Ziemssen F, Spital G, Liakopoulos S, Schmitz-Valckenberg S, Wiedon A, Holz FG. OCEAN Studie: Aktuelle Daten zum Versorgungsalltag von Patienten mit neovaskulärer AMD. Deutsche Ophthalmochirurgie (DOC), 2014 (Presentation)
  • Ziemssen F, Schmitz-Valckenberg S, Liakopoulos S, Spital G, Wiedon A, Holz FG. 12-month interim results of the real-life OCEAN study shows effectiveness of ranibizumab treatment across indications. American Academy of Ophthalmology (AAO), 2014 (Presentation)
  • Berk H, Holz FG, Liakopoulos S, Schmitz-Valckenberg S, Spital G, Ziemssen F, OCEAN-Study Group. Non-interventional trial to observe Lucentis treatment patterns in real-life conditions: Interim Results of the OCEAN Study. European School for Advanced Studies in Ophthalmology (ESASO), 2013 (Presentation)
  • o.V. OCEAN-Studie: Beobachtung von Therapieansätzen mit Lucentis® und routinemäßiger, ophthalmologischer Nachsorge einschließlich optionalem OCT bei den zugelassenen Indikationen. Makulaupdate, 2013 (Poster)
  • o.V. ORCA-Studie: Standardisierte Auswertung der SD-OCT-Befundung im Praxisalltag durch spezialisierte Reading Center. Makulaupdate, 2013 (Poster)
  • o.V. OCEAN Study – Non-interventional trial to observe Lucentis® treatment patterns in reallife conditions: Results of the first 1.000 Patients finishing 12 months of observation period. The European Society of Retina Specialists (EURETINA), 2013 (Presentation)
  • Schmitz-Valckenberg S, Brinkmann C, Heimes B, Holz FG, Kirchhoff B, Liakopolous S, Spital G, Ristau T, Wiedon A, Ziemssen F, ORCA-Study Group. Monitoring anti-VEGF therapy with SD-OCT. The ORCA Project. The European Society of Retina Specialists (EURETINA), 2013 (Presentation)
  • Spital G, Ziemssen F, Wiedon A, Schmitz-Valckenberg S, Scheidl S, Liakopoulos S, Holz FG, ORCA Investigators. ORCA - Standardisierte Auswertung der SD-OCT Befundung im Praxisalltag. German Ophthalmological Society (DOG), 2013 (Presentation)
  • Ziemssen F, Spital G, Liakopoulos S, Schmitz-Valckenberg S, Wiedon A, Scheidl S, Holz FG. OCEAN: Real-Life Studie zur Anwendung von Lucentis im Praxisalltag. Deutsche Ophthalmochirurgie (DOC), 2013 (Presentation)
  • Ziemssen F, Schmitz-Valckenberg S, Spital G, Liakopoulos S, Wiedon A, Scheidl S, Holz FG. ORCA: Evaluierung der SD-OCT Befundung in der täglichen Praxisroutine Deutsche Ophthalmochirurgie (DOC), 2013 (Presentation)
  • Ziemssen F, Wiedon A, Spital G, Schmitz-Valckenberg S, Scheidl S, Liakopoulos S, Holz FG, OCEAN Investigators. OCEAN – Beobachtung von Therapieansätzen mit Lucentis im Praxisalltag. German Ophthalmological Society (DOG), 2013 (Presentation)
NCT01594281 PRIDE, Phase II

Abstracts NCT01594281 PRIDE, Phase II

  • Liakopoulos S. Ranibizumab with or without PRP versus PRP alone in patients with PDR without DME - 24 months results. Imaging Meeting Milano, Milano, 2019 (Presentation)
  • Liakopoulos S, Lorenz K, Quiering C, Voegeler J, Spital G, Stahl A, Lang G. Änderung des Schweregrades einer diabetischen Retinopathie nach Ranibizumab vs panretinaler Laserkoagulation (PRP) vs Kombination bei PDR unter Verwendung von Weitfeld-Fluoreszenz-Angiographien sowie einem modifizierten ETDRS Grading: 12 Monats-Ergebnisse der PRIDE Studie. German Ophthalmological Society (DOG), 2018 (Presentation)
  • Liakopoulos S, Spital G, Lorenz K, Stahl A, Voegeler J, Quiering C, Lang G. Morphological outcomes of the PRIDE study using fluorescein angiography and a modified ETDRS severity scale grading for PDR-patients treated with ranibizumab and/or panretinal photocoagulation (PRP). The European Society of Retina Specialists (EURETINA), 2018 (Presentation)
  • Liakopoulos S, Spital G, Lorenz K, Quiering C, Voegeler J, Stahl A, Lang G. Outcome of proliferative diabetic retinopathy patients treated with ranibizumab, panretinal laser photocoagulation or a combination – Results of the PRIDE study. Retinologische Gesellschaft (RG), 2018 (Presentation)
  • Lang GE, Stahl A, Spital G, Lorenz K, Voegeler J, Quiering C, Liakopoulos S. Evaluation of ranibizumab and panretinal laser photocoagulation (PRP) in proliferative diabetic retinopathy (PDR) – 24-months observational follow-up of the PRIDE study The European Society of Retina Specialists (EURETINA), 2018 (Presentation)
  • Lang GE, Voegeler J, Quiering C, Spital G, Stahl A, Lorenz K, Liakopoulos S. Ranibizumab, panretinale Laserphotokoagulation (PRP) oder Kombination beider Therapien bei Proliferativer Diabetischer Retinopathie – 2-Jahresergebnisse der PRIDE Studie. German Ophthalmological Society (DOG), 2018 (Presentation)
  • Liakopoulos S, Stahl A, Spital G, Lorenz K, Voegeler J, Weiß C, Lang GE. Comparison of the efficacy of ranibizumab and panretinal laser photocoagulation in Proliferative Diabetic Retinopathy – 12-months results from the PRIDE Study American Academy of Ophthalmology (AAO), New Orleans, 2017 (Presentation)
  • Lang G, Stahl A, Spital G, Lorenz K, Voegeler J, Weiß C, Liakopoulos S. Comparison of the efficacy of ranibizumab and panretinal laser photocoagulation in Proliferative Diabetic Retinopathy – 12-months results from the PRIDE Study The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Lang GE, Voegeler J, Liakopoulos S, Weiß C, Gamulescu MA, Wiedemann P. Doppelt-maskierte Studie zeigt Überlegenheit von Ranibizumab plus Laser vs. alleinigem Laser bei Patienten mit Diabetischem Makulaödem mit oder ohne Proliferativer Diabetischer Retinopathie. German Ophthalmological Society (DOG), 2013 (Presentation)
NCT01958918 SALT, Phase IV

Abstracts NCT01958918 SALT, Phase IV

  • Liakopoulos S, Dahlke C, Stech M, Weiss C, Rose U, Paulus EM, Seitz B, Lorenz F, Holz A, Agostini H. Analyse diskrepanter Diagnosen in einer klinische Phase IV-Studie bei Patienten mit aktiver neovaskulärer AMD. Retinologische Gesellschaft (RG), 2017 (Presentation)
  • Agostini H, Dahlke C, Holz F, Liakopoulos S, Seitz B, Lorenz K, Silva R,. Comparison of central subfield retinal thickness (CSRT) stability in nAMD patients after administration of ranibizumab and aflibercept: – results of the SALT trial. The European Society of Retina Specialists (EURETINA), 2017 (Presentation)
  • Agostini H, Dahlke C, Stech M, Weiss C, Rose U, Paulus EM, Liakopoulos S, Seitz B, Lorenz K, Holz F. Beduetung der Stabilität der zentralen Netzhautdicke bei neovaskulärer AMD unter Therapie mit Ranibizumab oder Aflibercept - Ergebnisse der SALT Studie. German Ophthalmological Society (DOG), 2017 (Presentation)
NCT02257632 TIDE AMD, Phase IV

Abstracts NCT02257632 TIDE AMD, Phase IV

  • Wolf C, Junkes U, Rose P, Enders M, Maier, Liakopoulos S. A randomised trial assessing dynamics of systemic free VEGF-A in patients with age related macular degeneration treated with ranibizumab vs. aflibercept – Results from the TIDE-AMD trial. The European Society of Retina Specialists (EURETINA), 2018 (Presentation)
NCT01131585 RELATION, Phase IIIb

  • GE. Lang, S. Liakopoulos, J. Voegeler, C. Weiß, G. Spital, MA. Gamulescu, C. Lohmann, P. Wiedemann. In: Acta Ophtalmol. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema. 2018

Abstracts NCT01131585 RELATION, Phase IIIb 

  • Michels D, Schick T, Voegeler J, Weiss C, Spital G, Lang GE, Liakopoulos S. Impact of decentration of SDOCT volume scans on retinal thickness measurements in diabetic macula edema in a phase III multicenter randomized controlled trial (RELATION). The Association for Research in Vision and Ophthalmology (ARVO), 2015 (Poster)
  • Ristau T, Voegeler J, Lang GE, Liakopoulos S. Relevance of inner versus outer retinal thickness in diabetic macular edema in the RELATION study. The Association for Research in Vision and Ophthalmology (ARVO), 2013 (Poster)
  • Lang GE, Vögeler J, Liakopoulos S, Weiß C, Gamulescu A, Wiedemann P, RELATION Studiengruppe. Doppelt maskierte Studie RELATION zeigt Überlegenheit von Ranibizumab plus Laser vs. alleinigem Laser bei Patienten mit Diabetischem Makulaödem mit oder ohne Proliferativer Diabetischer Retinopathie. German Ophthalmological Society (DOG), 2012 (Presentation)

European Genetic Database (EUGENDA)

  • Ersoy L, Schick T, de Graft D, Felsch M, Hoyng CB, den Hollander AI, Kirchhof B, Fauser S, Liakopoulos S. Extramacular drusen are highly associated with age-related macular degeneration, but not with CFH and ARMS2 genotypes. Br J Ophthalmol. 2015 Nov 27. [Epub ahead of print]
  • Helgason H, Sulem P, Duvvari MR, Luo H, Thorleifsson G, Stefansson H, Jonsdottir I, Masson G, Gudbjartsson DF, Walters GB, Magnusson OT, Kong A, Rafnar T, Kiemeney LA, Schoenmaker-Koller FE, Zhao L, Boon CJ, Song Y, Fauser S, Pei M, Ristau T, Patel S, Liakopoulos S, van de Ven JP, Hoyng CB, Ferreyra H, Duan Y, Bernstein PS, Geirsdottir A, Helgadottir G, Stefansson E, den Hollander AI, Zhang K, Jonasson F, Sigurdsson H, Thorsteinsdottir U, Stefansson K. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. Nat Genet. 2013 Nov;45(11):1371-4.
  • Van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC, Nabuurs SB, Schoenmaker-Koller FE, Smailhodzic D, Campochiaro PA, Zack DJ, Duvvari MR, Bakker B, Paun CC, Boon CJ, Uitterlinden AG, Liakopoulos S, Klevering BJ, Fauser S, Daha MR, Katsanis N, Klaver CC, Blom AM, Hoyng CB, den Hollander AI. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet. 2013 Jul;45(7):813-7.
  • Ristau T, Ersoy L, Hahn M, den Hollander AI, Kirchhof B, Liakopoulos S, Fauser S. Nongenetic risk factors for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014 Jul 29;55(8):5228-32.

Abtracts European Genetic Database (EUGENDA)

  • Smailhodzic D, Liakopoulos S, Klevering BJ, Boon CJF, Kirchhof B, Daha MR, Klaver CCW, den Hollander AI, Hoyng CB. Evaluation of serum complement levels in age-related macular degeneration (AMD). o.J. (Presentation)
  • Boon CJF, van de Ven JPH, Smailhodzic D, Klevering BJ, Kirchhof B, Fauser S, Hoyng CB, den Hollander AI. Basal Laminar Drusen Are Highly Associated With Polymorphisms in the Complement Factor H (CFH) and Complement Component 3 (C3) Genes. The Association for Research in Vision and Ophthalmology (ARVO), 2010 (Presentation)
  • Den Hollander AI, Smailhodzic D, Khan HA, Omar A, Zhang AY, Kirchhof B, Chen J, Hoyng CB, Koenekoop RK, Fauser S. Pharmacogenetic Studies of Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration. The Association for Research in Vision and Ophthalmology (ARVO), 2010 (Presentation)
  • Smailhodzic D, Liakopoulos S, Klevering BJ, Boon CJF, Kirchhof B, Daha MR, Klaver CCW, den Hollander AI, Hoyng CB. Evaluation of Serum Complement Levels in Age-Related Macular Degeneration (amd). The Association for Research in Vision and Ophthalmology (ARVO), 2010 (Presentation)
  • Van de Ven JP, den Hollander AI, Boon CJF, Smailhodzic D, Klevering BJ, Klaver CCW, Fauser S, Hoyng CB. Novel Frameshift, Nonsense and Splice Site Mutations in the Complement Factor H Gene in Patients With Age-Related Maculopathy. The Association for Research in Vision and Ophthalmology (ARVO), 2010 (Presentation)
Nach oben scrollen